We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended June 2023, Organon (OGN - Free Report) reported revenue of $1.61 billion, up 1.5% over the same period last year. EPS came in at $1.31, compared to $1.25 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of +3.10%. The company delivered an EPS surprise of +35.05%, with the consensus EPS estimate being $0.97.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Women's Health - U.S.- Nexplanon/Implanon NXT: $159 million versus the three-analyst average estimate of $143.19 million.
Revenue- Women's Health - U.S.- Follistim AQ: $26 million versus $26.45 million estimated by three analysts on average.
Revenue- Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology- Other: $67 million versus the three-analyst average estimate of $64.28 million.
Revenue- Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology- Diprospan: $12 million compared to the $31.65 million average estimate based on three analysts.
Revenue- Women's Health - Nexplanon/Implanon NXT: $214 million versus the three-analyst average estimate of $212.52 million.
Revenue- Women's Health - Follistim AQ: $70 million compared to the $64.92 million average estimate based on three analysts.
Revenue- Biosimilars Total: $135 million versus $139.24 million estimated by three analysts on average.
Revenue- Women?s Health Total: $438 million compared to the $441.44 million average estimate based on three analysts.
Revenue- Established Brands - Other: $40 million versus the three-analyst average estimate of $41.81 million.
Revenue- Established Brands - Non-Opioid Pain, Bone and Dermatology - Other: $71 million versus the three-analyst average estimate of $67.78 million.
Revenue- Established Brands - Non-Opioid Pain, Bone and Dermatology - Diprospan: $12 million compared to the $31.65 million average estimate based on three analysts.
Revenue- Women's Health - NuvaRing: $40 million versus the three-analyst average estimate of $40.67 million.
Shares of Organon have returned +8% over the past month versus the Zacks S&P 500 composite's +2.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended June 2023, Organon (OGN - Free Report) reported revenue of $1.61 billion, up 1.5% over the same period last year. EPS came in at $1.31, compared to $1.25 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of +3.10%. The company delivered an EPS surprise of +35.05%, with the consensus EPS estimate being $0.97.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Women's Health - U.S.- Nexplanon/Implanon NXT: $159 million versus the three-analyst average estimate of $143.19 million.
- Revenue- Women's Health - U.S.- Follistim AQ: $26 million versus $26.45 million estimated by three analysts on average.
- Revenue- Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology- Other: $67 million versus the three-analyst average estimate of $64.28 million.
- Revenue- Established Brands - Int'l - Non-Opioid Pain, Bone and Dermatology- Diprospan: $12 million compared to the $31.65 million average estimate based on three analysts.
- Revenue- Women's Health - Nexplanon/Implanon NXT: $214 million versus the three-analyst average estimate of $212.52 million.
- Revenue- Women's Health - Follistim AQ: $70 million compared to the $64.92 million average estimate based on three analysts.
- Revenue- Biosimilars Total: $135 million versus $139.24 million estimated by three analysts on average.
- Revenue- Women?s Health Total: $438 million compared to the $441.44 million average estimate based on three analysts.
- Revenue- Established Brands - Other: $40 million versus the three-analyst average estimate of $41.81 million.
- Revenue- Established Brands - Non-Opioid Pain, Bone and Dermatology - Other: $71 million versus the three-analyst average estimate of $67.78 million.
- Revenue- Established Brands - Non-Opioid Pain, Bone and Dermatology - Diprospan: $12 million compared to the $31.65 million average estimate based on three analysts.
- Revenue- Women's Health - NuvaRing: $40 million versus the three-analyst average estimate of $40.67 million.
View all Key Company Metrics for Organon here>>>Shares of Organon have returned +8% over the past month versus the Zacks S&P 500 composite's +2.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.